PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Greenphire, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

N30 Pharma Selects Greenphire's Global Payment Technology Platforms - N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard to streamline payments to investigators & subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in March - Greenphire.com
N30 Pharma Selects Greenphire's Global Payment Technology Platforms

 

NewswireToday - /newswire/ - Orlando, FL, United States, 2013/04/17 - N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard to streamline payments to investigators & subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in March - Greenphire.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are compliant with relevant regulations, including the Sunshine Act.

N30 Pharma will use the eClinicalGPS platform to automate payments to investigative sites involved in the trial.

The company will use the ClinCard platform to reimburse subjects and to arrange subject travel, thereby reducing costs and administrative complexities associated with the trial.

N30 Pharma CFO Tom Sokolowski said,"Using Greenphire's systems will ensure that our staff and investigators can focus entirely on the scientific and patient-centric elements of the study while remaining confident that payments are accurate, quick, and fully accounted for."

Greenphire CEO and Co-Founder Sam Whitaker said that the company is looking forward to collaborate with N30 Pharma on its first clinical trial in cystic fibrosis which it hopes will eventually result in new, effective treatments for the disease.

"By using Greenphire's payment platforms to manage the payment and subject travel aspects of the trial, N30 Pharma can reduce costs and risk, remain compliant with relevant regulations, and spend less time managing the logistical aspects of the study," Whitaker added.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greenphire, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


N30 Pharma Selects Greenphire's Global Payment Technology Platforms

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Greenphire |
Publisher Contact: Press Office - Greenphire.com 
215-609-4378 / 215-609-4640 corporate[.]greenphire.com / sales[.]greenphire.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greenphire, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greenphire, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)